Protein-sugar conjugation with sodium cyanoborohydride

By controlling the sodium borohydride content in sodium cyanoborohydride and using 1-dimensional proton NMR to quantify, the problems of quantitative difficulties and reaction interference are solved, and the efficiency of the conjugation reaction and the purity of the product are improved.

CN118984718APending Publication Date: 2024-11-19SANOFI VACCINES US INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033151.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-05-10
Filing Date
2023-04-10
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

It is difficult to accurately determine the content of sodium borohydride in sodium cyanoborohydride, and its presence will interfere with the conjugation reaction of protein carriers and sugars. The commonly used NMR method has background signal interference, affecting quantitative accuracy.

Method used

The amount of sodium borohydride is determined by controlling the sodium borohydride content in the sodium cyanoborohydride reagent without exceeding 0.7%, using 1-dimensional proton NMR to determine the amount of sodium borohydride and conjugate the sugar with protein carrier under this condition. In combination, the characteristic split mode and temperature control of NMR are utilized to reduce interference.

Benefits of technology

The relative quantification of sodium borohydride in sodium cyanoborohydride is achieved, and the conjugation reaction efficiency between sugar and protein carrier is improved while controlling the content of sodium borohydride, reducing the generation of impurities, improving the accuracy of the reaction and purity of the product.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118984718A_ABST
    Figure CN118984718A_ABST
Patent Text Reader

Abstract

Disclosed herein are methods and uses for conjugating sugars to protein carriers. Exemplary conjugates prepared according to those methods and uses are also disclosed. In addition, methods for quantifying the amount of sodium borohydride in a sodium cyanoborohydride reagent are disclosed herein. Vaccine compositions and related methods and uses are also disclosed herein.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63 / 329,547, filed on April 11, 2022, and European Patent Application No. 22172626.8, filed on May 10, 2022, both of which are hereby incorporated by reference in their entirety. Background and Summary of the Invention

[0002] Sodium cyanoborohydride (NaCNBH3) is used in various chemical reactions. For example, sodium cyanoborohydride reagents are often used for conjugation of protein carriers with sugars. Because sodium borohydride (NaBH4) is a stronger reducing agent than sodium cyanoborohydride, the presence of sodium borohydride in the reaction may produce impurities in the final product.

[0003] However, it is unclear how much sodium borohydride is present in the sodium cyanoborohydride reagent that would potentially interfere with the conjugation of the protein carrier to the sugar, and existing methods for detecting sodium borohydride do not provide quantification of the amount of sodium borohydride in the sodium cyanoborohydride sample and present additional challenges. 11 BNMR is more accurate than proton NMR (also known as 1 H NMR) is even less common because 11 BNMR requires a tunable broadband probe. In addition, typical NMR tubes used for analysis and sometimes the NMR probes themselves are made of borosilicate glass. However, this type of glass is 11 B NMR spectra give a broad background signal which interferes with the baseline of the NMR spectrum, which may prevent accurate integration and quantification.

[0004] It is described herein that even small amounts of sodium borohydride in sodium cyanoborohydride may adversely affect the conjugation reaction of a sugar and a protein carrier. Thus, the present disclosure provides a method for conjugating at least one activated sugar to at least one protein carrier, the method comprising reacting the at least one activated sugar with the at least one protein carrier in the presence of a sodium cyanoborohydride reagent containing no more than about 0.7% sodium borohydride to obtain a conjugate. In addition, it is reported that 1 H NMR is able to distinguish sodium cyanoborohydride from sodium borohydride within a sample and can be used for the relative quantification of sodium borohydride contained in a sodium cyanoborohydride sample.

[0005] According to the present specification, methods and uses of conjugating sugars to protein carriers are disclosed herein. Exemplary conjugates prepared according to those methods and uses are also disclosed herein. In addition, methods for quantifying the amount of sodium borohydride in a sodium cyanoborohydride reagent are disclosed herein. In addition, vaccine compositions and related methods and uses are also disclosed herein.

[0006] Thus, the following embodiments are provided. Embodiment 1 is a method for conjugating at least one activated sugar to at least one protein carrier, the method comprising: (a) determining the amount of sodium borohydride in a sodium cyanoborohydride reagent; and (b) reacting the at least one activated sugar with the at least one protein carrier in the presence of a sodium cyanoborohydride reagent containing no more than about 0.7% sodium borohydride to obtain a conjugate.

[0007] Example 2 is the use of a sodium cyanoborohydride reagent containing no more than about 0.7% sodium borohydride as a reagent for conjugating at least one activated sugar to at least one protein carrier by reductive amination, wherein the sodium cyanoborohydride reagent has been determined to contain no more than 0.7% sodium borohydride.

[0008] Embodiment 3 is the use of a sodium cyanoborohydride reagent containing no more than about 0.7% sodium borohydride as a reagent in conjugating at least one activated sugar to at least one protein carrier by reductive amination, the use comprising: (a) determining the amount of sodium borohydride in the sodium cyanoborohydride reagent; and (b) reacting the at least one activated sugar with the at least one protein carrier in the presence of the sodium cyanoborohydride reagent containing no more than about 0.7% sodium borohydride to obtain a conjugate.

[0009] Embodiment 4 is the method or use according to any one of the preceding embodiments, wherein the method further comprises activating at least one sugar with an activating agent to obtain the at least one activated sugar.

[0010] Embodiment 5 is a method or use according to any one of the preceding embodiments, wherein the sodium cyanoborohydride reagent contains no more than about 0.6% sodium borohydride.

[0011] Embodiment 6 is the method or use according to the preceding embodiment, wherein the sodium cyanoborohydride reagent contains no more than about 0.5% sodium borohydride.

[0012] Embodiment 7 is a method or use according to any one of the preceding embodiments, wherein the at least one activated sugar comprises an activated form of a surface carbohydrate of a cell or virus.

[0013] Embodiment 8 is the method or use according to any one of the preceding embodiments, wherein the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide.

[0014] Embodiment 9 is the method or use according to any one of the preceding embodiments, wherein the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide from Haemophilus influenzae.

[0015] Embodiment 10 is the method or use of any one of embodiments 1 to 8, wherein the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide from Streptococcus pneumoniae.

[0016] Embodiment 11 is the method or use of any one of embodiments 1 to 8, wherein the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide from Neisseria meningitidis.

[0017] Embodiment 12 is a method or use according to the preceding embodiment, wherein the Neisseria meningitidis is serogroup C, A, W-135 or Y

[0018] Embodiment 13 is a method or use according to any one of the preceding embodiments, wherein the at least one protein vector comprises recombinant extracellular protein alpha (REP A), outer membrane protein complex (OMPC), diphtheria toxoid, CRM197, tetanus toxoid or tetanus toxin C fragment.

[0019] Embodiment 14 is the method or use according to any one of the preceding embodiments, wherein the at least one protein carrier comprises diphtheria toxoid, CRM197 or tetanus toxoid.

[0020] Embodiment 15 is the method or use according to any one of the preceding embodiments, wherein the at least one protein carrier comprises tetanus toxoid.

[0021] Embodiment 16 is the method or use according to any one of the preceding embodiments, wherein the pH of the reaction is in the range of from about 7 to about 10.

[0022] Embodiment 17 is the method or use according to any one of the preceding claims, wherein the pH of the reaction is about 8.

[0023] Embodiment 18 is the method or use according to any one of embodiments 1-16, wherein the pH of the reaction is about 9.

[0024] Embodiment 19 is the method or use according to any one of the preceding embodiments, wherein the determining the amount of sodium borohydride comprises performing NMR on the sodium cyanoborohydride reagent.

[0025] Embodiment 20 is the method or use according to the preceding embodiment, wherein the NMR comprises 1-dimensional proton NMR.

[0026] Example 21 is a method for quantifying the amount of sodium borohydride in a sodium cyanoborohydride reagent, the method comprising: (a) performing 1-dimensional proton NMR on a sample of the sodium cyanoborohydride reagent to obtain NMR data; and (b) determining the amount of sodium borohydride in the sample from the NMR data.

[0027] Embodiment 22 is the method or use according to any one of embodiments 19-21, wherein the NMR is performed in a deuterated solvent comprising one or more deuterated forms of at least one of dimethyl sulfoxide, chloroform or dichloromethane.

[0028] Embodiment 23 is the method or use according to embodiments 19-22, wherein the NMR comprises at least one scan with a relaxation delay of about 41 to 50 seconds.

[0029] Embodiment 24 is the method or use according to embodiment 23, wherein the NMR comprises at least one scan with a relaxation delay of about 43 to 48 seconds.

[0030] Embodiment 25 is the method or use according to embodiment 24, wherein the NMR comprises at least one scan with a relaxation delay of about 45 seconds.

[0031] Embodiment 26 is the method or use according to any one of embodiments 19-25, wherein the NMR is performed at a temperature ranging from about 20°C to about 45°C.

[0032] Embodiment 27 is the method or use according to embodiment 26, wherein the NMR is performed at a temperature ranging from about 28°C to about 40°C.

[0033] Embodiment 28 is the method or use according to embodiment 27, wherein the NMR is performed at a temperature ranging from about 30°C to about 35°C.

[0034] Embodiment 29 is the method or use according to embodiment 28, wherein the NMR is performed at a temperature of about 30°C.

[0035] Embodiment 30 is a method or use according to any one of embodiments 19-29, wherein the NMR is performed with the following parameters - temperature: about 30°C; pulse width: pw90; spectrum width: 7000 Hz; relaxation delay: about 45 seconds.

[0036] Embodiment 31 is a method or use according to any one of embodiments 19-30, wherein determining the amount of sodium borohydride comprises using the peak area of ​​the sodium borohydride resonance at about 0.57 ppm, as referenced to the solvent resonance.

[0037] Embodiment 32 is a method or use according to embodiment 31, wherein the solvent resonance comprises a dimethyl sulfoxide resonance at about 2.5 ppm.

[0038] Embodiment 33 is a method or use according to any one of embodiments 19-32, wherein determining the amount of sodium borohydride uses an external standard curve of sodium borohydride, optionally wherein the external standard curve of sodium borohydride is from about 20-120 μg / ml.

[0039] Embodiment 34 is a method or use according to embodiment 33, wherein the external standard curve comprises a 6-point external standard curve.

[0040] Embodiment 35 is a conjugate produced according to the method or use of any one of embodiments 1-20 and 22-34.

[0041] Embodiment 36 is a vaccine composition comprising at least one protein-conjugated sugar obtained according to any one of embodiments 1-20 and 22-34.

[0042] Embodiment 37 is the vaccine composition according to embodiment 36, further comprising a pharmaceutically acceptable buffer.

[0043] Embodiment 38 is the vaccine composition of embodiment 36 or 37, further comprising a pharmaceutically acceptable salt.

[0044] Embodiment 39 is the vaccine composition of any one of embodiments 36-38, formulated for intramuscular administration.

[0045] Embodiment 40 is a method of vaccinating a subject, the method comprising administering a dose of the vaccine composition according to any one of Embodiments 36-39.

[0046] Embodiment 41 is the use of the vaccine composition according to any one of embodiments 36-39 for immunizing a subject.

[0047] Embodiment 42 is the use of the vaccine composition according to any one of embodiments 36-39 for the manufacture of a medicament for immunizing a subject.

[0048] Embodiment 43 is the method or use according to any one of embodiments 40-42, wherein the subject is immunized against Haemophilus influenzae.

[0049] Embodiment 44 is the method or use according to any one of embodiments 40-42, wherein the subject is immunized against Neisseria meningitidis.

[0050] Embodiment 45 is the method or use according to any one of embodiments 40-42, wherein the subject is immunized against S. pneumoniae.

[0051] Embodiment 46 is the method or use according to any one of embodiments 40-45, wherein the vaccine composition is administered intramuscularly.

[0052] Embodiment 47 is a method of preparing a vaccine composition, comprising conjugating at least one activated sugar to at least one protein carrier according to the method or use of any one of embodiments 1-20 or 22-34; and formulating the conjugate into a vaccine composition.

[0053] Embodiment 48 is a method for preparing at least one vaccine composition comprising a conjugate, the method comprising the steps of: (a) determining the amount of sodium borohydride in a sodium cyanoborohydride reagent, (b) selecting a sodium cyanoborohydride reagent containing no more than about 0.7% sodium borohydride, (c) reacting at least one activated sugar with at least one protein carrier in the presence of the selected sodium cyanoborohydride reagent to provide at least one conjugate, and (d) formulating the at least one conjugate into a vaccine composition.

[0054] Embodiment 49 is a method according to embodiment 48, wherein the method further comprises activating at least one sugar with an activating agent to obtain the at least one activated sugar.

[0055] Embodiment 50 is the method of embodiment 48 or 49, wherein the selected sodium cyanoborohydride reagent contains no more than about 0.6% sodium borohydride.

[0056] Embodiment 51 is the method according to the preceding embodiment, wherein the selected sodium cyanoborohydride reagent contains no more than about 0.5% sodium borohydride.

[0057] Embodiment 52 is the method of any one of embodiments 48-51, wherein the at least one activated sugar comprises an activated form of a surface carbohydrate of a cell or virus.

[0058] Embodiment 53 is the method of any one of embodiments 48-52, wherein the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide.

[0059] Embodiment 54 is the method of any one of embodiments 48-53, wherein the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide from Haemophilus influenzae.

[0060] Embodiment 55 is the method of any one of embodiments 48-53, wherein the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide from Streptococcus pneumoniae.

[0061] Embodiment 56 is the method of any one of embodiments 48-53, wherein the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide from Neisseria meningitidis.

[0062] Embodiment 57 is a method according to the preceding embodiment, wherein the Neisseria meningitidis is serogroup C, A, W-135 or Y.

[0063] Embodiment 58 is a method according to any one of embodiments 48-57, wherein the at least one protein vector comprises recombinant extracellular protein alpha (REP A), outer membrane protein complex (OMPC), diphtheria toxoid, CRM197, tetanus toxoid or tetanus toxin C fragment.

[0064] Embodiment 59 is the method according to the preceding embodiment, wherein the at least one protein carrier comprises diphtheria toxoid, CRM197 or tetanus toxoid.

[0065] Embodiment 60 is a method according to the preceding embodiment, wherein the at least one protein carrier comprises tetanus toxoid.

[0066] Embodiment 61 is a conjugate for use as a vaccine according to any one of embodiments 36-39.

[0067] Embodiment 62 is a vaccine according to any one of embodiments 36-39 for use in preventing infection or disease caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae.

[0068] Embodiment 63 is a vaccine according to any one of embodiments 36-39 for use in immunizing against Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae.

[0069] Embodiment 64 is a conjugate for use in the manufacture of a vaccine according to any one of embodiments 36-39.

[0070] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0071] Figure 1 Shown are the 1-D proton NMR spectra of sodium borohydride and sodium cyanoborohydride, as discussed in Example 1.

[0072] Figure 2A Shown are the results of a temperature study of the 1-D proton NMR spectra of sodium borohydride and sodium cyanoborohydride, as discussed in Example 1.

[0073] Figure 2B The corresponding Figure 2A The NMR data shown are overlays of the borohydride peaks.

[0074] Figure 3 Shown are the results of a 1-D proton NMR study of various sodium cyanoborohydride samples, as discussed in Example 1.

[0075] Figure 4 The integrated value of the sodium borohydride peak is shown, as discussed in Example 1.

[0076] Figure 5 Shown is an array of spectra from a sodium cyanoborohydride sample doped with sodium borohydride, as discussed in Example 1.

[0077] Figure 6 A linear curve generated using sodium borohydride concentration is shown relative to the peak area obtained from a sample of sodium borohydride in d-DMSO, as discussed in Example 1.

[0078] Figure 7 Shown is a linear curve generated using sodium borohydride concentration versus the peak area obtained from sodium cyanoborohydride samples spiked with varying amounts of sodium borohydride, as discussed in Example 1.

[0079] Figure 8 The linear relationship of target (sodium borohydride) relative to observed sodium borohydride in the sodium cyanoborohydride sample is shown, as discussed in Example 2.

[0080] Fig. 9 Shown is a HPSEC chromatogram (absorbance 280 nm) of the conjugation reaction between the activated intermediate serogroup W-135 polysaccharide and tetanus toxoid, as discussed in Example 3.

[0081] Fig.10 Shown is a HPSEC chromatogram (absorbance 280 nm) of the conjugation reaction between activated intermediate serogroup Y polysaccharide and tetanus toxoid, as discussed in Example 3.

[0082] Fig.11 Shows Fig.10 Magnified view of a region of the conjugate chromatogram shown in .

[0083] Fig.12 Shown is a HPSEC chromatogram (absorbance 280 nm) of the conjugation reaction between an intermediate serogroup C polysaccharide and tetanus toxoid, as discussed in Example 3.

[0084] Fig.13 Shown is a HPSEC chromatogram (absorbance 280 nm) of the conjugation reaction between an intermediate serogroup W-135 polysaccharide and tetanus toxoid, as discussed in Example 3. DETAILED DESCRIPTION

[0085] Reference will now be made in detail to certain embodiments of the present invention, examples of which are shown in the accompanying drawings. Although embodiments of the present invention will be described, it will be understood that they are not intended to limit the present invention to those embodiments. On the contrary, the present invention is intended to encompass all alternatives, modifications and equivalents of the embodiments described herein.

[0086] Before describing the present teachings in detail, it should be understood that the present disclosure is not limited to specific compositions or process steps and may therefore vary. It should be noted that, as used in this specification and the appended claims, the singular forms "a / an" and "the" include plural referents unless the context clearly dictates otherwise. Similarly, it should be understood that the phrase "at least one" includes one and a plurality. Thus, for example, it should be understood that the phrases "a / a conjugate" and "at least one conjugate" both include one and a plurality.

[0087] Numerical ranges include the numbers that define the range. Taking into account significant figures and errors associated with measurement, measured values ​​and measurable values ​​should be understood to be approximate. In addition, the use of "comprise", "comprises", "comprising", "contain", "contains", "containing", "include", "includes" and "including" is not intended to be limiting. It should be understood that the above general description and detailed description are exemplary and explanatory only, and are not limiting of the teachings.

[0088] Unless otherwise indicated, embodiments in the specification that list "comprising" various components are also considered to be "consisting of" or "consisting essentially of" the listed components; embodiments in the specification that list "consisting of" various components are also considered to be "containing" or "consisting essentially of" the listed components; and embodiments in the specification that list "consisting essentially of" various components are also considered to be "consisting of" or "including the listed components" (this interchangeability does not apply to the use of these terms in the claims).

[0089] The section headings used herein are for organizational purposes only and should not be interpreted in any way as limiting the desired subject matter. If any document incorporated by reference conflicts with any term defined in this specification, the present specification shall prevail. Although the present teachings are described in conjunction with various embodiments, it is not intended that the present teachings be limited to these embodiments. On the contrary, as will be appreciated by those skilled in the art, the present teachings include various alternatives, modifications, and equivalents. A. Definition

[0090] Unless otherwise stated, the following terms and phrases as used herein are intended to have the following meanings:

[0091] The term "percent" or "%" in relation to the amount of sodium borohydride in the sodium cyanoborohydride reagent refers to the weight percentage. For example, 5 μg of sodium borohydride in a 5 mg sample of the sodium cyanoborohydride reagent would be 0.5%.

[0092] Unless the context requires otherwise, the word "or" is used in an inclusive sense, ie, equivalent to "and / or".

[0093] The terms "linker" and "bond" are used interchangeably and mean a chemical moiety comprising a chain of atoms that is covalently attached or attached to an item such as a carrier protein or sugar.

[0094] "Linking moiety" means a chemically reactive group, substituent or moiety, such as a nucleophile or electrophile, that is capable of reacting with another molecule to form a bond via a covalent bond.

[0095] "Spacer" is used herein to mean a linker made of carbon atoms. For example, a spacer may contain 2-10 linear carbon atoms.

[0096] The term "sugar" includes both monosaccharides and polysaccharides.

[0097] The term "polysaccharide" refers to a chain of covalently linked monosaccharide units, which may be linear or branched. In some embodiments, the polysaccharide has a molecular weight (eg, weight average molecular weight or number average molecular weight) in the range of 300 kDa to 1500 kDa.

[0098] The term "about" indicates a degree of variation that does not substantially affect the properties of the described subject matter, for example, within 10%, 5%, 2% or 1%. Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. B. Exemplary methods and uses of conjugating at least one activated sugar to at least one protein carrier and exemplary conjugates produced according to those methods and uses

[0099] In some embodiments, a method for conjugating at least one activated sugar to at least one protein carrier is provided. In some embodiments, the method comprises reacting at least one activated sugar with the at least one protein carrier. In some embodiments, the method comprises reacting at least one activated sugar with the at least one protein carrier in the presence of a sodium cyanoborohydride reagent containing no more than about 0.7% sodium borohydride to obtain a conjugate. Unless otherwise indicated, percentage concentrations herein and throughout are w / w.

[0100] In some embodiments, a sodium cyanoborohydride reagent is provided as a reagent for conjugating at least one activated sugar to at least one protein carrier by reductive amination. In some embodiments, the use comprises using a sodium cyanoborohydride reagent containing no more than about 0.7% sodium borohydride as a reagent in conjugating at least one activated sugar to at least one protein carrier by reductive amination.

[0101] The general characteristics of the procedure for conjugating sugars to protein carriers using sodium cyanoborohydride are available, for example, in U.S. Pat. No. 4,365,170; U.S. Pat. No. 4,673,574; EP 0161188; EP 0208375; EP 0477508; and WO 2018 / 045286. These documents do not discuss the limitation of the amount of sodium borohydride in the sodium cyanoborohydride reagent.

[0102] In some embodiments, the methods or uses disclosed herein comprise direct reductive amination.

[0103] In some embodiments, in the methods and uses disclosed herein, the at least one activated sugar is directly conjugated to the at least one carrier protein. In some embodiments, the at least one activated sugar is indirectly conjugated to an amino group on the at least one carrier protein via a linker group. In some embodiments, the linker group comprises a carbonyl, a carbamate, a spacer, an amide, or a hydrazide linker. In some embodiments, the linker group comprises a dihydrazide linker.

[0104] In some embodiments, the methods and uses disclosed herein further comprise activating at least one sugar with an activator to obtain the at least one activated sugar. Depending on the structure of the at least one polysaccharide, different activation strategies can be applied to the at least one polysaccharide to facilitate covalent coupling to a carrier protein. See, e.g., Vaccine Analysis: Strategies, Principles, and Control; Nunnally, BK, Turula, VE, Sitrin, RD, eds.; Springer: Berlin / Heidelberg, Germany, 2015; pp. 313-320.

[0105] Methods for activating sugars can be achieved by procedures known in the art - see, for example, WO 2018 / 045286, which describes an exemplary activation procedure. A general review of various activation strategies can be found in Vaccine Analysis: Strategies, Principles, and Control [Vaccine Analysis: Strategies, Principles, and Control]; Nunnally, BK, Turula, VE, Sitrin, RD, eds.; Springer: Berlin / Heidelberg, Germany, 2015; pp. 313-320.

[0106] In some embodiments, activation is achieved by reacting the sugar with sodium periodate, 1-ethyl-3-(-3 dimethylaminopropyl) carbodiimide hydrochloride (EDAC), 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP), or carbonyldiimidazole (CDI). In some embodiments, the sugar is activated to introduce an aldehyde moiety to provide an activated sugar. In some embodiments, introduction of the aldehyde moiety is achieved by reacting the sugar with sodium periodate.

[0107] In some embodiments, the activated sugar is a sugar comprising a moiety suitable for conjugation to a protein carrier in a reaction (e.g., in the presence of a cyanoborohydride reagent, such as a reductive amination reaction). In some embodiments, moieties suitable for conjugation to a protein carrier in a reaction include esters, aldehydes, -OCN, -CN, -OC(O)NH(CH2)3NH2, -NH2, -NHNHC(O)(CH2) n C(O)NHNH2, -NHC(O)(CH2) n C(O)O-pyrrolidine-2,5-dione, -NHC(O)CH2SH and -NHC(O)(CH2) n C≡CH, where n is in each case the number of CH2 units in the chain.

[0108] In some embodiments, the sodium cyanoborohydride reagent of the methods and uses disclosed herein contains no more than about 0.6% sodium borohydride. In some embodiments, the sodium cyanoborohydride reagent contains no more than about 0.5% sodium borohydride.

[0109] Any known sugar can be used in the methods and uses disclosed herein - see, e.g., WO 2018 / 045286; WO 2008 / 135514; U.S. Pat. No. 7,862,823. In some embodiments, in the methods and uses disclosed herein, the at least one activated sugar comprises an activated form of a surface carbohydrate of a cell or virus. Exemplary cell types include bacteria, protozoa, worms, fungi, and cancer cells. See, e.g., Astronomo et al., "Carbohydrate vaccines: developing sweet solutions to sticky solutions?" Nat. Rev. Drug Discov., April 2010, 9(4): 10.1038 / nrd3012.

[0110] In some embodiments, in the methods and uses disclosed herein, the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide. Capsular polysaccharides can be prepared according to known methods. See, for example, Example 1 of U.S. Patent Application Publication No. 2003 / 0068336; U.S. Patent No. 6,933,137.

[0111] In some embodiments, the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide from Haemophilus influenzae. In some embodiments, the Haemophilus influenzae is Haemophilus influenzae type b. In some embodiments, the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide from Streptococcus pneumoniae. In some embodiments, the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide from Neisseria meningitidis. In some embodiments, the Neisseria meningitidis is serogroup C, A, W-135 or Y.

[0112] Any known protein carrier can be used in the methods and uses disclosed herein. Examples of protein carriers are discussed in, for example, Pichichero ME. "Protein carriers of conjugate vaccines: Characteristics, development, and clinical trials." Human Vaccines & Immunotherapeutics, 2013; 9(12): 2505-2523. Doi: 10.4161 / hv.26109, which is incorporated herein by reference. In some embodiments, in the methods and uses disclosed herein, the at least one protein carrier comprises recombinant extracellular protein alpha (REP A), outer membrane protein complex (OMPC), diphtheria toxoid, CRM197, tetanus toxoid, or tetanus toxin C fragment. In some embodiments, the at least one protein carrier comprises diphtheria toxoid, CRM197, or tetanus toxoid. In some embodiments, the at least one protein carrier comprises tetanus toxoid. In some embodiments, the tetanus toxoid is a genetically detoxified tetanus toxoid.

[0113] In some embodiments, the tetanus toxoid (TT) is prepared by extracting the toxin from a culture of Clostridium tetani (Harvard strain) grown in Mueller and Miller medium or modified Mueller and Miller medium, ammonium sulfate purification, and formalin inactivation. In some embodiments, TT is processed to reduce residual formaldehyde, concentrated in sodium chloride, and filter sterilized. In some embodiments, TT is purified by chromatography rather than ammonium sulfate purification. In some embodiments, the modified Mueller and Miller medium does not contain beef heart extract powder. In some embodiments, the Clostridium tetani is grown in the medium described in Table 3, page 16 of WO 2006 / 042542.

[0114] In some embodiments, in the methods and uses disclosed herein, the pH of the reaction is in the range of from about 7 to about 10. In some embodiments, the pH is about 7, 8, 9, or 10. In some embodiments, the pH is about 7, 7.5, 8, 8.5, 9, 9.5, or 10. In some embodiments, the pH is about 7, 7.25, 7.5, 7.75, 8, 8.25, 8.50, 8.75, 9, 9.25, 9.5, 9.75, or 10. In some embodiments, the pH is about 8. In some embodiments, the pH is about 9.

[0115] In some embodiments, the methods and uses disclosed herein further include determining the amount of sodium borohydride in the sodium cyanoborohydride reagent. In some embodiments, the quantification includes performing NMR on the sodium cyanoborohydride reagent. In some embodiments, the NMR includes 1-dimensional proton NMR.

[0116] In some embodiments, conjugates of at least one activated sugar and at least one protein carrier are provided. In some embodiments, the conjugates are produced according to the methods and uses disclosed herein.

[0117] In some embodiments, the conjugate may be a polysaccharide of Haemophilus influenzae conjugated to a recombinant extracellular protein alpha (REP A), an outer membrane protein complex (OMPC), a diphtheria toxoid, CRM197, a tetanus toxoid, or a tetanus toxin C fragment. In some embodiments, the conjugate may be a polysaccharide of Streptococcus pneumoniae conjugated to a recombinant extracellular protein alpha (REP A), an outer membrane protein complex (OMPC), a diphtheria toxoid, CRM197, a tetanus toxoid, or a tetanus toxin C fragment. In some embodiments, the conjugate may be a polysaccharide of Neisseria meningitidis conjugated to a recombinant extracellular protein alpha (REP A), an outer membrane protein complex (OMPC), a diphtheria toxoid, CRM197, a tetanus toxoid, or a tetanus toxin C fragment. In some embodiments, the conjugate is a polysaccharide of Neisseria meningitidis conjugated to a tetanus toxoid conjugate. C. Exemplary Method for Quantifying the Amount of Sodium Borohydride in Sodium Cyanoborohydride Reagent

[0118] In some embodiments, a method for quantifying the amount of sodium borohydride in a sodium cyanoborohydride reagent is provided. In some embodiments, the method comprises performing a 1-dimensional proton NMR on a sample of the sodium cyanoborohydride reagent to obtain NMR data. In some embodiments, the method comprises determining the amount of sodium borohydride in the sample from the NMR data.

[0119] In some embodiments, in the methods disclosed herein, the NMR is performed in a deuterated solvent. In some embodiments, the deuterated solvent comprises one or more deuterated forms of at least one of dimethyl sulfoxide, chloroform, or dichloromethane. In some embodiments, the NMR is performed in deuterated dimethyl sulfoxide.

[0120] In some embodiments, in the methods disclosed herein, the NMR comprises at least one scan with a relaxation delay of about 41 to 50 seconds. In some embodiments, the NMR comprises at least one scan with a relaxation delay of about 43 to 48 seconds. In some embodiments, the NMR comprises at least one scan with a relaxation delay of about 45 seconds.

[0121] In some embodiments, in the methods disclosed herein, the NMR is performed at a temperature ranging from about 20°C to about 45°C. In some embodiments, the NMR is performed at a temperature ranging from about 28°C to about 40°C. In some embodiments, the NMR is performed at a temperature ranging from about 30°C to about 35°C. In some embodiments, the NMR is performed at a temperature of about 30°C.

[0122] In some embodiments, in the methods disclosed herein, the NMR is performed with the following parameters: temperature - about 30°C; pulse width - pw90; spectrum width - 7000 Hz; and relaxation delay - about 45 seconds.

[0123] In some embodiments, in the methods disclosed herein, the determining step comprises using a peak area of ​​a sodium borohydride resonance at about 0.57 ppm as reference to a solvent resonance. In some embodiments, in the methods disclosed herein, the solvent resonance comprises a dimethyl sulfoxide resonance at about 2.5 ppm.

[0124] In some embodiments, in the methods disclosed herein, the determining step uses an external standard curve. In some embodiments, the external standard is an external standard of about 20-120 μg / ml sodium borohydride. In some embodiments, the external standard curve comprises a 6-point external standard curve. D. Exemplary Vaccine Compositions and Related Methods and Uses

[0125] In some embodiments, a vaccine composition is provided. In some embodiments, the vaccine composition comprises at least one protein-conjugated sugar. In some embodiments, the at least one protein-conjugated sugar is produced according to the methods and uses disclosed herein.

[0126] The formulation of the vaccine compositions disclosed herein can be achieved using art-recognized methods. The selection of appropriate carriers and other additives will depend on the exact route of administration and the nature of the particular dosage form.

[0127] In some embodiments, the at least one protein-conjugated sugar is purified. A method for purification involving ultrafiltration in the presence of ammonium sulfate is described in U.S. Pat. No. 6,146,902. Alternatively, the conjugate can be purified from unreacted protein and polysaccharide by any number of standard techniques, including size exclusion chromatography, density gradient centrifugation, hydrophobic interaction chromatography, mixed mode resin chromatography, or ammonium sulfate fractionation. See, e.g., PW Anderson et al. (1986). J. Immunol. [Journal of Immunology] 137: 1181-1186; see also HJ Jennings and C. Lugowski (1981) J. Immunol. [Journal of Immunology] 127: 1011-1018.

[0128] In some embodiments, the vaccine composition disclosed herein further comprises a pharmaceutically acceptable preservative, carrier, buffer excipient, etc. In one embodiment, the pharmaceutically acceptable preservative, carrier or excipient increases or extends the shelf life of the composition.

[0129] In some embodiments, the vaccine composition disclosed herein comprises a buffer, such as a pharmaceutically acceptable buffer. In some embodiments, the pharmaceutically acceptable buffer comprises a phosphate buffer, an acetate buffer, a borate buffer, a histidine buffer or a succinate buffer. In some embodiments, the pharmaceutically acceptable buffer comprises sodium phosphate. In some embodiments, the pharmaceutically acceptable buffer comprises sodium acetate. In some embodiments, the buffer is present in a concentration ranging from about 10mM to 100mM, for example, 10mM to 70mM, 15mM to 45mM, 20mM to 40mM, 40mM to 60mM or 60mM to 100mM. In some embodiments, the buffer is present in 30mM. In some embodiments, the buffer has a pH of 4.5 to 7.5, 4.5 to 7.0, 4.5 to 6.5, 4.5 to 6.0, 4.5 to 5.5 or 4.5 to 5.0. In some embodiments, the buffer has a pH ranging from 5.5 to 7.0, such as 5.75 to 6.25, or 6.25 to 6.75. In some embodiments, the buffer has a pH of 5.5 to 6.5. In some embodiments, the buffer has a pH of 5 or 6.

[0130] In some embodiments, the vaccine compositions disclosed herein further comprise a pharmaceutically acceptable salt. In some embodiments, the vaccine compositions disclosed herein comprise saline. In some embodiments, the saline comprises or is NaCl. The NaCl can be present at a concentration of 0.45% to 0.9% w / v, such as 0.5% to 0.85% w / v, or 0.6% to 0.8% w / v, or 0.6%, 0.67%, 0.75%, 0.8%, 0.85%, or 0.9%. In some embodiments, the NaCl can be present at a concentration of about 0.67%.

[0131] In some embodiments, the vaccine compositions disclosed herein contain one or more adjuvants. By way of example and not limitation, adjuvants include aluminum adjuvants, Freund's adjuvants, BAY, DC-chol, pcpp, monophosphoryl lipid A, CpG, QS-21, cholera toxin, and formylmethionyl peptides. See, for example, Vaccine Design, the Subunit and Adjuvant Approach, 1995 (edited by M.F. Powell and M.J. Newman, Plenum Press, New York). The adjuvant, if present, can be an aluminum adjuvant, such as aluminum hydroxide or aluminum phosphate. In some embodiments, the vaccine compositions disclosed herein do not contain an adjuvant. In some embodiments, the vaccine compositions disclosed herein contain an adjuvant.

[0132] In some embodiments, the vaccine compositions disclosed herein are formulated for intramuscular administration. In some embodiments, the administration is subcutaneous, intradermal, intraperitoneal, parenteral, or intravenous. The composition can be mixed with a suitable carrier, diluent, or excipient (such as a sodium acetate buffered saline solution, sterile water, physiological saline, etc.). The compositions disclosed herein can also be lyophilized. The compositions disclosed herein can contain auxiliary substances, such as wetting agents or emulsifiers, pH buffers, gelling agents or viscosity enhancing additives, preservatives, etc., depending on the route of administration and the desired formulation. Suitable formulations can be prepared by reference to standard texts, such as "REMINGTON’S PHARMACEUTICAL SCIENCE", 17th edition, 1985, which is incorporated herein by reference, without undue experimentation.

[0133] In some embodiments, the vaccine compositions disclosed herein are provided as a liquid formulation. In some embodiments, the liquid formulation is provided in a syringe, such as a pre-filled and / or silicone-free syringe. In some embodiments, such syringes are commercially packaged for sale and / or distribution.

[0134] In some embodiments, the vaccine compositions disclosed herein can be administered as a single dose or in a series (i.e., with one or more "boosters"), or as a booster after an earlier administration of a different vaccine (such as a Neisseria meningitidis capsular saccharide conjugate vaccine). For example, a child may receive a single dose early in life, followed by a booster dose up to ten years later, as currently recommended for other vaccines to prevent childhood diseases. In some embodiments, a dose of a vaccine disclosed herein is administered two months to ten years after a prior administration of a vaccine, such as two months to four months, four months to six months, six months to twelve months, one year to two years, two years to three years, three years to four years, four years to five years, five years to six years, six years to seven years, seven years to eight years, eight years to nine years, or nine years to ten years after a prior administration of a vaccine.

[0135] In some embodiments, the vaccine composition disclosed herein is formulated as a single unit dose. In some embodiments, the single unit dose comprises from about 2 μg to about 15 μg of sugar. In some embodiments, the single unit dose comprises about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 μg of sugar. In some embodiments, the single unit dose comprises about 2 μg of sugar. In some embodiments, the single unit dose comprises about 4 μg of sugar. In some embodiments, the single unit dose comprises about 10 μg of sugar. In some embodiments, wherein the vaccine is a multivalent vaccine, the single unit dose comprises from about 2 μg to about 15 μg of each of a variety of sugars.

[0136] In some embodiments, the carrier protein is present in an amount from about 15 μg to about 80 μg in a single unit dose. In some embodiments, the carrier protein is present in an amount of about 15, 20, 30, 40, 50, 60, 70 or 80 μg in a single unit dose. In some embodiments, the carrier protein is present in an amount of about 15 μg to about 30 μg in a single unit dose. In some embodiments, the carrier protein is present in an amount of about 30 μg to about 45 μg in a single unit dose. In some embodiments, the carrier protein is present in an amount of about 45 μg to about 65 μg in a single unit dose. In some embodiments, the carrier protein is present in an amount of about 25 μg in a single unit dose. In some embodiments, the carrier protein is present in an amount of about 55 μg in a single unit dose.

[0137] In some embodiments, a method of vaccinating a subject is provided. In some embodiments, the method comprises administering a dose of the vaccine composition disclosed herein. In some embodiments, use of the vaccine composition for immunizing a subject is provided. In some embodiments, the use comprises administering a dose of the vaccine composition disclosed herein. In some embodiments, use of the vaccine composition for manufacturing a medicament for immunizing a subject is provided. In some embodiments, the use comprises administering the vaccine composition disclosed herein.

[0138] In some embodiments, in the methods or uses disclosed herein, the subject is immunized against Haemophilus influenzae. In some embodiments, the Haemophilus influenzae is Haemophilus influenzae type b. In some embodiments, the subject is immunized against Neisseria meningitidis. In some embodiments, the subject is immunized against Streptococcus pneumoniae.

[0139] In some embodiments, in the methods or uses disclosed herein, the vaccine composition is administered intramuscularly. In some embodiments, the administration is subcutaneous, intradermal, intraperitoneal, parenteral or intravenous. The composition can be mixed with a suitable carrier, diluent or excipient (such as a sodium acetate buffered saline solution, sterile water, physiological saline, etc.). The compositions disclosed herein can also be lyophilized. The compositions disclosed herein can contain auxiliary substances such as wetting agents or emulsifiers, pH buffers, gelling agents or viscosity enhancing additives, preservatives, etc., depending on the route of administration and the desired formulation. Suitable formulations can be prepared by referring to standard texts such as "REMINGTON'S PHARMACEUTICAL SCIENCE", 17th Edition, 1985, which is incorporated herein by reference, without undue experimentation.

[0140] In some embodiments, a method of preparing a vaccine composition is disclosed herein. In some embodiments, the method comprises conjugating at least one activated sugar with the at least one protein carrier. In some embodiments, conjugating at least one activated sugar with at least one protein carrier is carried out according to the methods or uses disclosed herein. In some embodiments, the method further comprises formulating the conjugate into a vaccine composition.

[0141] In some embodiments, a method of preparing at least one vaccine composition comprising a conjugate is provided. In some embodiments, the method comprises the steps of: determining the amount of sodium borohydride in a sodium cyanoborohydride reagent; selecting a sodium cyanoborohydride reagent containing no more than about 0.7% sodium borohydride; reacting at least one activated sugar with at least one protein carrier in the presence of the selected sodium cyanoborohydride reagent to provide at least one conjugate; and formulating the at least one conjugate into a vaccine composition.

[0142] In some embodiments, the methods disclosed herein further comprise activating at least one saccharide with an activating agent to obtain the at least one activated saccharide. As discussed above, activation methods are known in the art.

[0143] In some embodiments, in the methods disclosed herein, the selected sodium cyanoborohydride reagent contains no more than about 0.6% sodium borohydride. In some embodiments, the selected sodium cyanoborohydride reagent contains no more than about 0.5% sodium borohydride.

[0144] In some embodiments, in the methods disclosed herein, the at least one activated sugar comprises an activated form of a surface carbohydrate of a cell or virus. In some embodiments, the at least one activated sugar comprises an activated form of a bacterial capsular polysaccharide. In some embodiments, the at least one activated sugar comprises an activated form of a bacterial capsular polysaccharide from Haemophilus influenzae. In some embodiments, the Haemophilus influenzae is Haemophilus influenzae type b. In some embodiments, the at least one activated sugar comprises an activated form of a bacterial capsular polysaccharide from Streptococcus pneumoniae. In some embodiments, the at least one activated sugar comprises an activated form of a bacterial capsular polysaccharide from Neisseria meningitidis. In some embodiments, the Neisseria meningitidis is serogroup C, A, W-135 or Y.

[0145] In some embodiments, in the methods disclosed herein, the at least one protein vector comprises recombinant extracellular protein alpha (REP A), outer membrane protein complex (OMPC), diphtheria toxoid, CRM197, tetanus toxoid, or tetanus toxin C fragment. In some embodiments, the at least one protein vector comprises diphtheria toxoid, CRM197, or tetanus toxoid. In some embodiments, the at least one protein vector comprises tetanus toxoid. In some embodiments, the at least one protein vector comprises genetically detoxified tetanus toxoid. Examples

[0146] The following are examples of methods, uses, conjugates and compositions disclosed herein. It should be understood that, given the general and detailed descriptions provided above, various other embodiments may be practiced. The following examples are given for the purpose of illustrating the present teachings and should not be construed as limiting the scope of the present disclosure or claims.

[0147] Abbreviations used: Example 1. Development of a quantitative 1D proton NMR method for quantifying sodium borohydride in the raw material sodium cyanoborohydride

[0148] The amount of NaBH4 in the NaCNBH4 reagent was determined using 1-D proton NMR. The method used used an external 6-point standard curve of sodium borohydride from about 20-120 μg / mL with a quantitation range of about 30-300 μg / mL and a quantitation limit of about 30 μg / mL.

[0149] Quantitation was achieved by linear regression using the peak area of ​​the sodium borohydride peak at a chemical shift value of approximately -0.57 ppm, as referenced to the dimethyl sulfoxide resonance at 2.5 ppm.

[0150] Initial method development

[0151] To evaluate the feasibility of the method, a sample consisting of 50 mg / mL sodium cyanoborohydride and 0.050 mg / mL sodium borohydride was prepared in d-DMSO. NMR analysis was performed using the instrument parameters in Table 1 below. Table 1: Acquisition parameters parameter value Temperature (temp) 30℃ Receiver gain 36 Pulse width (sw) pw90 Spectral width (sw) 7000Hz Points (np) 64K Scan / transient number (nt) 32 Steady state pulse (ss) 4 Relaxation delay (d1) 45

[0152] Proton NMR of borohydride compounds

[0153] The resonances in the proton spectra of sodium borohydride and sodium cyanoborohydride show splitting patterns due to bonding with boron. Boron has two magnetically active isotopes 11 B and 10 B, whose properties are shown in Table 2 below. In the proton spectrum, the signal is split by coupling with the boron nucleus. 11 At the higher natural abundance of B and spin = 3 / 2, four singlets of equal intensity are observed. Figure 1 .on the contrary, 10 The lower natural abundance and spin = 3 of B produces a seven-line multiplet at much lower intensity. See supra.

[0154] The fragmentation patterns are similar in both sodium borohydride and sodium cyanoborohydride; however, the chemical shift and line width of sodium cyanoborohydride are different due to the presence of the cyano group. Figure 1 . Table 2: NMR properties of boron

[0155] Temperature study

[0156] For accurate integration, the peaks of interest need to be baseline separated. In particular, if an internal standard is used, the overlap of the sodium borohydride and sodium cyanoborohydride resonances introduces a significant source of error if integration is performed over the entire resonance (i.e., all peaks of the analyte). Figure 1As shown, there is overlap between sodium borohydride and sodium cyanoborohydride. The resonances of sodium cyanoborohydride show slight changes in chemical shift values ​​by changing the temperature, however, baseline separation is not achieved even at elevated temperatures. See Figure 2. Therefore, an acquisition temperature of 30°C was maintained.

[0157] Materials without sodium borohydride

[0158] Various batches of sodium cyanoborohydride were prepared for NMR analysis in order to find batches of material that did not contain measurable amounts of sodium borohydride. Figure 3 Because Batch 4 did not show any measurable amounts of sodium borohydride, this material was selected for the method development work.

[0159] Peaks used for quantification

[0160] As previously in Figure 1 As shown in , the overlap of sodium cyanoborohydride resonance with some sodium borohydride peaks will lead to quantitative errors. Figure 4 The integrated values ​​of all sodium borohydride peaks in batch 4 spiked with 50 μg / mL sodium borohydride are shown. The presence of the large sodium cyanoborohydride resonance contributes to the distortion of the baseline of the leftmost sodium borohydride resonance. The resonance at -0.57 ppm exhibits a flat baseline and is well resolved from adjacent peaks. Therefore, this peak was selected for quantitation.

[0161] Determination of spin-lattice relaxation time

[0162] Inversion recovery experiments are performed to determine the spin-lattice relaxation time (T1) of the analyte. T1 is a measure of the time required for each nucleus to reach equilibrium with its surroundings in a magnetic field. An accurate estimate of T1 ensures sufficient relaxation delay (d2) between scans to allow the magnetization to return to equilibrium. For experiments where multiple scans are collected (nt>1), if too short a d2 value is used, the magnetization will not fully recover to its equilibrium value before the next scan is started, resulting in integration errors.

[0163] In an inversion recovery experiment, the magnetization (M0) is reversed with a 180° pulse and then a time τ (d2) is applied to allow relaxation. A 90° observation pulse is applied to measure the magnetization after the time τ. In this experiment, the value of τ (or d2) is arranged.

[0164] A 50 mg / ml sodium cyanoborohydride sample from batch 4 spiked with 0.05 mg / mL sodium borohydride was used for the experiment. The acquisition parameters were 16 scans, a relaxation delay of 45 seconds, a 90 pulse width of 8.3 microseconds, a 180 pulse width of 16.6 microseconds at an emitter power of 57 dB, a temperature of 30° C., an acquisition time of 8.194 s, and d2 was arranged into 15 points for the time between pulses of 0.010 seconds to 60 seconds. The scan width was 7998.4 Hz with 128K of acquisition data points.

[0165] Varian software T1 analysis was used, and the following equation was used for peak height and T1 analysis: M = M0 (1-2e -τ / T 1).

[0166] The relaxation delay (d2), i.e. the time delay between pulse scans in the experiment, is at least five times the longest T1. With the T1 value of the sodium borohydride resonance being about 8 s (i.e., 5*T1 = about 40 s), a value of 45 s for d1 is a sufficient relaxation delay time between pulse scans.

[0167] The array spectrum of the T1 experiment is Figure 5 The analysis results are shown in Table 3 below. Table 3: Sodium borohydride spin-lattice relaxation time Peak chemical shift T1(s) Error(s) -0.077* 5.38 0.123 -0.24 7.95 0.0758 -0.40 8.06 0.0947 -0.57 7.97 0.129 e overlaps with the peak of cyanoborohydride

[0168] Initial recovery study

[0169] Sodium borohydride in dimethyl sulfoxide-d6 - A stock solution of 4.7 mg / ml sodium borohydride in DMSO-d6 was prepared. 750 ml of sample was prepared ranging from 6 to 295 ppm. NMR analysis was performed using the following instrumental parameters: temperature 30°C, receiver gain 30, 90° pulse width (8.3 μs), spectral width 7998.4 Hz, and 64K acquisition point. After four steady-state scans, 32 scans were acquired with a relaxation delay of 45 seconds. A linear curve was generated using sodium borohydride concentration versus the resonance peak area at -0.57 ppm. See Figure 6 .

[0170] Sodium Borohydride in Sodium Cyanoborohydride Sample Matrix - A 50 mg / mL sodium cyanoborohydride stock solution was prepared. Using a 4.7 mg / ml sodium borohydride stock solution, samples with different sodium borohydride concentrations were prepared for NMR analysis. Figure 7 A data table and a plot of concentration versus peak area for the experiment are shown. Example 2. Method evaluation

[0171] Accuracy, Precision and Linearity

[0172] A 50 mg / ml sodium cyanoborohydride solution was prepared. In this sample matrix, five levels of sodium borohydride were prepared at 31, 104, 183, 261 and 313 μg / mL. Three samples were analyzed at each level. A six-point external calibration curve was used.

[0173] Table 4 below shows the results of the study. Level 1 corresponds to 31 μg / mL; Level 2 corresponds to 104 μg / mL; Level 3 corresponds to 183 μg / mL; Level 4 corresponds to 261 μg / mL; and Level 5 corresponds to 313 μg / mL. For accuracy, 80%-120% is considered good, with closer to 100% being best. For precision, less than 15% is acceptable, but the lower the better. As shown below, the method showed good accuracy and precision (% relative standard deviation). Figure 8 A linear relationship of the target (ie, expected borohydride) in sodium cyanoborohydride relative to the observed sodium borohydride is shown. Table 4: Accuracy, Repeatability and Intermediate Precision Example 3. Threshold at which sodium borohydride contamination negatively affects the conjugation reaction The aim of this study was to determine the threshold at which sodium borohydride contamination negatively affects the conjugation reaction.

[0174] Effectiveness of polysaccharide activation prior to conjugation

[0175] The activated polysaccharide intermediates (Neisseria meningitidis polysaccharide serogroups C, W-135 and Y activated by sodium periodate) were tested for reducing activity to determine the effectiveness of polysaccharide activation. The assay is a colorimetric assay and is based on the formation of a purple complex by bicinchoninic acid (BCA) in an alkaline solution that has a strong affinity for Cu +2 Cu ions obtained through reducing sugar activity + ions. This test is an indicator for determining the ability of the activated polysaccharide to conjugate with tetanus protein in a conjugation reaction. A review of the reduction activity results showed that the polysaccharide was effectively activated and suitable for conjugation.

[0176] Suitability of tetanus toxoid

[0177] A review of the protein content of tetanus toxoid batches used for conjugation was completed. More specifically, the BCA (bicinchoninic acid) protein assay was adapted from the BCA colorimetric assay for protein described by Smith et al., Analytical Biochemistry 1985; 150(1):76-85. When combined with sample protein, the Cu from the BCA working reagent +2 Reduced to Cu +1 Each Cu +1 The ion combines with two BCA molecules to form BCA-Cu +1 The complex produced a purple color showing strong absorbance at 562 nm. The protein concentration was found to be suitable for conjugation.

[0178] Suitability of sodium cyanoborohydride for conjugation

[0179] The purpose of this study was to perform an initial screen to determine the threshold at which sodium borohydride contamination would negatively affect the conjugation reaction.Four experiments were performed with sodium borohydride concentrations of 0.5%, 1.0%, 1.5%, and 2.0%.

[0180] Sodium cyanoborohydride was used in the conjugation reaction during the manufacture of the Neisseria meningitidis polysaccharide tetanus toxoid conjugate concentrates of serogroups C, W-135, and Y. The pH of the conjugation reaction was 8 for serogroup C and 9 for serogroups W-135 and Y.

[0181] During the conjugation reaction, polysaccharides exceeding tetanus are added to ensure that tetanus is fully utilized. Conjugate concentrates are made by covalently attaching depolymerized / activated polysaccharides to tetanus toxoid carrier proteins. This attachment occurs via the reductive amination of aldehyde groups on the polysaccharide chain with amine groups present on the tetanus toxoid carrier protein. In this reaction, sodium cyanoborohydride specifically reduces the Schiff base intermediate formed between the polysaccharide aldehyde group and the protein amine group to form a stable secondary amine bond. The resulting conjugate has a polysaccharide chain connected to the protein carrier. The reaction is allowed to mix for 16-24 hours. After the allowed mixing time, the conjugation reaction is then terminated by adding sodium borohydride. Sodium borohydride reduces the remaining aldehyde groups to hydroxyl groups, thereby inhibiting further conjugation. If there is a trace amount of sodium borohydride during the conjugation reaction, sodium borohydride will reduce the amount of aldehyde groups available for attachment to the protein carrier, thereby producing free protein.

[0182] HPSEC analysis was performed to determine the differences in the size of the conjugate molecules. Larger molecules flow through the SEC column faster than smaller molecules. Therefore, a shift toward longer retention times indicates a smaller conjugate size corresponding to an effect on reaction efficiency.

[0183] (1) Serogroup W Neisseria meningitidis polysaccharide tetanus toxoid conjugate concentrate: The starting materials used were activated intermediate serogroup W-135 polysaccharide and tetanus toxoid. Pharmaceutical grade, 97.5% pure sodium cyanoborohydride was used for the purpose of this study. Sodium borohydride was then spiked into the sodium cyanoborohydride stock solution at various concentrations and then allowed to mix for 24 hours. After 24 hours, all samples were removed and run on a HPSEC column to determine the efficiency of the reaction. The chromatogram (absorbance 280 nm) was at Fig. 9 Shown in.

[0184] The results of this study indicated that concentrations ≥ 1.0% negatively impacted the conjugation reaction - ie, left a significant amount of free protein in the reaction.

[0185] (2) Serogroup Y Neisseria meningitidis polysaccharide-tetanus toxoid conjugate concentrate: The starting materials used were activated intermediate serogroup Y polysaccharide and tetanus toxoid. Pharmaceutical grade, 97.5% pure sodium cyanoborohydride was used for the purposes of this study, except for the control group where reagent grade sodium cyanoborohydride was used. Sodium borohydride was then spiked into the sodium cyanoborohydride stock solution at various concentrations (0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%) and then allowed to mix for 24 hours. After 24 hours, all samples were removed and run on a size exclusion chromatography column to determine the efficiency of the reaction. The HPSEC chromatogram (absorbance 280 nm) was at Fig.10 and Fig.11 The same type of results (similar structure and same conjugation process) are expected for serogroup W polysaccharides. The results of this study indicate that concentrations ≥ 0.7% have a negative impact on the conjugation reaction.

[0186] Free protein results

[0187] A total of 8 runs of Neisseria meningitidis polysaccharide tetanus toxoid conjugate concentrates (see Table 5 below) were successfully produced according to the method described in WO 2018 / 045286 to complete the evaluation of the impact of residual sodium borohydride present in the sodium cyanoborohydride.

[0188] The experiment consisted of four control groups and four experimental groups spiked with sodium borohydride at 0.5% and 1.0% concentrations. Pharmaceutical and reagent grade sodium cyanoborohydride were used for the purpose of this study. The appropriate amount of sodium borohydride was spiked into the sodium cyanoborohydride stock solution at a predetermined concentration prior to delivery into the conjugation reaction. Table 5: Description of experimental groups

[0189] The material is then processed to complete via diafiltration, hydrophobic interaction chromatography purification and final diafiltration. After the 16-24 hour retention time ends, HPSEC samples are taken out from the crude conjugate mixture. These samples are taken out to determine whether the chromatogram is offset towards a longer retention time. Longer retention time indicates the potential impact on the conjugation reaction.

[0190] Serum Group C chromatograms between pharmaceutical and reagent grade controls ( Fig.12 ) showed no significant difference. The serum group C chromatograms showed a slight shift for the 0.5% sodium borohydride sample and a significant shift for the 1.0% sodium borohydride sample. The significant shift in the 1% chromatogram indicated that the 1% sodium borohydride content may have a negative impact on the reaction efficiency.

[0191] Serum group W-135 chromatogram ( Fig.13 ) showed no significant differences between runs 1, 2, and 3. However, serum group W-135 (1.0% sodium borohydride) did show a significant shift, indicating that the presence of 1% sodium borohydride content may have a negative impact on reaction efficiency.

[0192] It has been shown that batches of sodium cyanoborohydride containing 0.5% sodium borohydride have no negative impact on the free protein content of the final bulk concentrate. However, batches containing at least 1% sodium borohydride content may result in an increase in the free protein content. Equivalent

[0193] The foregoing written description is deemed sufficient to enable those skilled in the art to practice the embodiments. The foregoing description and examples detail certain embodiments and describe the best mode contemplated by the inventors. However, it will be understood that no matter how much detail the foregoing may appear in text form, the present embodiments may be practiced in many ways and should be interpreted according to the appended claims and any equivalents thereof.

[0194] As used herein, the term approximately refers to a numerical value, including, for example, integers, fractions, and percentages, whether or not explicitly indicated. The term approximately generally refers to a numerical range (e.g., + / - 5%-10% of the listed range) that one of ordinary skill in the art would consider equivalent to the listed value (e.g., having the same function or result). When a term (such as at least and approximately) precedes a list of numerical values ​​or ranges, these terms modify all values ​​or ranges provided in the list. In some cases, the term approximately may include a numerical value rounded to the nearest significant figure.

Claims

1. A method for conjugating at least one activated sugar to at least one protein carrier, the method comprising: a) determining the amount of sodium borohydride in the sodium cyanoborohydride reagent; and b) reacting the at least one activated sugar with the at least one protein carrier in the presence of a sodium cyanoborohydride reagent containing no more than about 0.7% of sodium borohydride to obtain a conjugate.

2. Use of a sodium cyanoborohydride reagent containing no more than about 0.7% sodium borohydride as a reagent for conjugating at least one activated sugar to at least one protein carrier by reductive amination, wherein the sodium cyanoborohydride reagent has been determined to contain no more than 0.7% sodium borohydride.

3. Use of a sodium cyanoborohydride reagent containing no more than about 0.7% sodium borohydride as a reagent for conjugating at least one activated sugar to at least one protein carrier by reductive amination, the use comprising: a) determining the amount of sodium borohydride in the sodium cyanoborohydride reagent; and b) reacting the at least one activated sugar with the at least one protein carrier in the presence of a sodium cyanoborohydride reagent containing no more than about 0.7% of sodium borohydride to obtain a conjugate.

4. The method or use according to any one of the preceding claims, wherein the method further comprises activating at least one sugar with an activating agent to obtain the at least one activated sugar.

5. The method or use according to any one of the preceding claims, wherein the sodium cyanoborohydride reagent contains no more than about 0.6% sodium borohydride.

6. The method or use according to the preceding claim, wherein the sodium cyanoborohydride reagent contains no more than about 0.5% sodium borohydride.

7. The method or use according to any one of the preceding claims, wherein the at least one activated sugar comprises an activated form of a surface carbohydrate of a cell or virus.

8. The method or use according to any one of the preceding claims, wherein the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide.

9. The method or use according to any one of the preceding claims, wherein the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide from Haemophilus influenzae.

10. The method or use according to any one of claims 1 to 8, wherein the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide from Streptococcus pneumoniae.

11. The method or use according to any one of claims 1 to 8, wherein the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide from Neisseria meningitidis.

12. The method or use according to the preceding claim, wherein the Neisseria meningitidis is of serogroup C, A, W-135 or Y.

13. The method or use according to any one of the preceding claims, wherein the at least one protein carrier comprises recombinant extracellular protein alpha (REP A), outer membrane protein complex (OMPC), diphtheria toxoid, CRM197, tetanus toxoid or tetanus toxin C fragment.

14. The method or use according to any one of the preceding claims, wherein the at least one protein carrier comprises diphtheria toxoid, CRM197 or tetanus toxoid.

15. The method or use according to any one of the preceding claims, wherein the at least one protein carrier comprises tetanus toxoid.

16. The method or use according to any one of the preceding claims, wherein the pH of the reaction is in the range of from about 7 to about 10.

17. The method or use according to any one of the preceding claims, wherein the pH of the reaction is about 8.

18. The method or use according to any one of claims 1-16, wherein the pH of the reaction is about 9.

19. The method or use according to any one of the preceding claims, wherein the determining the amount of sodium borohydride comprises performing NMR on the sodium cyanoborohydride reagent.

20. The method or use according to the preceding claim, wherein the NMR comprises 1-dimensional proton NMR.

21. A method for quantifying the amount of sodium borohydride in a sodium cyanoborohydride reagent, the method comprising: (a) performing 1D proton NMR on a sample of a sodium cyanoborohydride reagent to obtain NMR data; and (b) Determine the amount of sodium borohydride in the sample from the NMR data.

22. The method or use according to any one of claims 19-21, wherein the NMR is performed in a deuterated solvent comprising one or more deuterated forms of at least one of dimethyl sulfoxide, chloroform or dichloromethane.

23. The method or use according to claims 19-22, wherein the NMR comprises at least one scan with a relaxation delay of about 41 to 50 seconds.

24. The method or use according to claim 23, wherein the NMR comprises at least one scan with a relaxation delay of about 43 to 48 seconds.

25. The method or use according to claim 24, wherein the NMR comprises at least one scan with a relaxation delay of about 45 seconds.

26. The method or use according to any one of claims 19-25, wherein the NMR is performed at a temperature ranging from about 20°C to about 45°C.

27. The method or use according to claim 26, wherein the NMR is performed at a temperature ranging from about 28°C to about 40°C.

28. The method or use according to claim 27, wherein the NMR is performed at a temperature ranging from about 30°C to about 35°C.

29. The method or use according to claim 28, wherein the NMR is performed at a temperature of about 30°C.

30. The method or use according to any one of claims 19-29, wherein the NMR is performed with the following parameters: -Temperature: about 30℃ -Pulse width: pw90 - Spectral width: 7000Hz - Relaxation delay: about 45 seconds.

31. The method or use of any one of claims 19-30, wherein determining the amount of sodium borohydride comprises using the peak area of ​​the sodium borohydride resonance at about 0.57 ppm as referenced to the solvent resonance.

32. The method or use of claim 31, wherein the solvent resonance comprises a dimethyl sulfoxide resonance at about 2.5 ppm.

33. The method or use of any one of claims 19-32, wherein determining the amount of sodium borohydride uses an external standard curve of sodium borohydride, optionally wherein the external standard curve of sodium borohydride is from about 20-120 μg / ml.

34. The method or use of claim 33, wherein the external standard curve comprises a 6-point external standard curve.

35. A conjugate produced according to the method or use of any one of claims 1-20 and 22-34.

36. A vaccine composition comprising at least one protein-conjugated sugar obtained according to any one of claims 1-20 and 22-34.

37. The vaccine composition of claim 36, further comprising a pharmaceutically acceptable buffer.

38. The vaccine composition according to claim 36 or 37, further comprising a pharmaceutically acceptable salt.

39. The vaccine composition according to any one of claims 36-38, formulated for intramuscular administration.

40. A method of vaccinating a subject, the method comprising administering a dose of the vaccine composition according to any one of claims 36-39.

41. Use of the vaccine composition according to any one of claims 36-39 for immunizing a subject.

42. Use of the vaccine composition according to any one of claims 36-39 for the manufacture of a medicament for immunizing a subject.

43. The method or use of any one of claims 40-42, wherein the subject is immunized against Haemophilus influenzae.

44. The method or use of any one of claims 40-42, wherein the subject is immunized against Neisseria meningitidis.

45. The method or use of any one of claims 40-42, wherein the subject is immunized against S. pneumoniae.

46. ​​The method or use according to any one of claims 40-45, wherein the vaccine composition is administered intramuscularly.

47. A method of preparing a vaccine composition, the method comprising conjugating at least one activated sugar to at least one protein carrier according to the method or use of any one of claims 1-20 or 22-34; and formulating the conjugate into a vaccine composition.

48. A method of preparing at least one vaccine composition comprising a conjugate, the method comprising the steps of: a) Determine the amount of sodium borohydride in the sodium cyanoborohydride reagent, b) selecting a sodium cyanoborohydride reagent containing no more than about 0.7% sodium borohydride, c) reacting at least one activated sugar with at least one protein carrier in the presence of the selected sodium cyanoborohydride reagent to provide at least one conjugate, and d) formulating the at least one conjugate into a vaccine composition.

49. The method of claim 48, wherein the method further comprises activating at least one sugar with an activating agent to obtain the at least one activated sugar.

50. The method of claim 48 or 49, wherein the selected sodium cyanoborohydride reagent contains no more than about 0.6% sodium borohydride.

51. The method according to the preceding claim, wherein the selected sodium cyanoborohydride reagent contains no more than about 0.5% sodium borohydride.

52. The method of any one of claims 48-51, wherein the at least one activated sugar comprises an activated form of a surface carbohydrate of a cell or virus.

53. The method of any one of claims 48-52, wherein the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide.

54. The method of any one of claims 48-53, wherein the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide from Haemophilus influenzae.

55. The method of any one of claims 48-53, wherein the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide from Streptococcus pneumoniae.

56. The method of any one of claims 48-53, wherein the at least one activated saccharide comprises an activated form of a bacterial capsular polysaccharide from Neisseria meningitidis.

57. The method according to the preceding claim, wherein the Neisseria meningitidis is of serogroup C, A, W-135 or Y.

58. The method of any one of claims 48-57, wherein the at least one protein vector comprises recombinant extracellular protein alpha (REP A), outer membrane protein complex (OMPC), diphtheria toxoid, CRM197, tetanus toxoid, or tetanus toxin C fragment.

59. The method according to the preceding claim, wherein the at least one protein carrier comprises diphtheria toxoid, CRM197 or tetanus toxoid.

60. The method according to the preceding claim, wherein the at least one protein carrier comprises tetanus toxoid.

61. A conjugate for use as a vaccine according to any one of claims 36-39.

62. The vaccine of any one of claims 36-39 for use in preventing Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae infection or disease.

63. The vaccine according to any one of claims 36 to 39 for use in immunization against Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae.

64. A conjugate for use in the manufacture of a vaccine according to any one of claims 36-39.